Eloxx Pharmaceuticals (ELOX) SEC Filings

Eloxx Pharmaceuticals, Inc. (ELOX) updated its resale prospectus for selling stockholders covering 600,000 shares of common stock and up to 4,358,919 shares issuable upon exercise of pre-funded warrants. The warrants have a $0.11-per-share exercise price, are exercisable at any time and expire when exercised in full, subject to the beneficial ownership limitation.

The board increased from five to six directors on October 19, 2026, appointing Geno J. Germano for a term expiring at the 2027 annual meeting and until a successor is duly elected and qualified. Germano received an option to purchase up to 13,587 shares at $12.50 per share, vesting in 24 substantially equal monthly installments on the last day of each month, subject to continued service. Eloxx also appointed T.R. Srinivas, M.D., Senior Vice President and Chief Medical Officer, and described its EXPRESS Phase 2 trial for approximately 60 adults with PKD1 or PKD2 nonsense mutations, randomized 1:1 to exaluren or placebo for 52 weeks. The primary endpoint is the annualized rate of change in height-adjusted total kidney volume; first dosing is expected in the third quarter of 2027 and topline data in the first half of 2029.

Eloxx Pharmaceuticals, Inc. (ELOX) lists Geno J. Germano as a director in an initial beneficial ownership statement. A power of attorney is attached as Exhibit 24.

Eloxx Pharmaceuticals, Inc. (ELOX) expanded its board from five to six directors on October 19, 2026, appointing Geno J. Germano to the new seat. His term runs through the 2027 annual meeting and until a successor is elected and qualified or his earlier death, disqualification, resignation or removal; the board determined he is independent under Nasdaq listing standards, company policies and SEC rules. Germano received an option to purchase up to 13,587 common shares at $12.50 per share. The award vests and becomes exercisable in 24 substantially equal monthly installments, subject to continued service as a non-employee director through each vesting date.

On October 20, 2026, Eloxx announced T.R. Srinivas, M.D., as Senior Vice President and Chief Medical Officer and finalized the design of EXPRESS, a global Phase 2 trial of exaluren for nonsense-mutation autosomal dominant polycystic kidney disease. The trial is designed to enroll approximately 60 adults with PKD1 or PKD2 nonsense mutations, randomized 1:1 to exaluren or placebo for 52 weeks; its primary endpoint is annualized rate of change in height-adjusted total kidney volume. First patient dosing is expected in the third quarter of 2027, with topline data expected in the first half of 2029. Exaluren has received orphan drug designations for ADPKD in the United States and Europe.

Eloxx Pharmaceuticals, Inc. (ELOX) has filed a Form S-1 registering a resale offering for selling stockholders of 600,000 shares of common stock plus up to 4,358,919 additional shares issuable upon exercise of outstanding pre-funded warrants. Eloxx is not selling any shares in this registration.

The pre-funded warrants were issued in prior private placements, carry a cash exercise price of $0.11 per share, are exercisable at any time and remain outstanding until fully exercised, subject to a beneficial ownership limitation. Eloxx will receive no proceeds from stockholder resales, but would receive about $0.5 million if all pre-funded warrants are exercised for cash. As of June 30, 2026, 4,036,398 shares of common stock were outstanding, and the stock traded at $16.28 per share on Nasdaq on September 10, 2026.

Eloxx is a clinical-stage biopharmaceutical company focused on ribosome-modulating small molecules targeting nonsense mutations, led by exaluren for rare kidney diseases, with additional programs in autosomal dominant polycystic kidney disease and a partnered asset, ZKN-013, licensed to Almirall. The company reports an accumulated deficit of $308.8 million, continued operating losses, prior Nasdaq delisting and filing delinquencies, and states its existing cash and cash equivalents are expected to fund current and planned operations at least twelve months from this prospectus date and currently to mid-2028.

Investment entities affiliated with Samsara BioCapital and Srinivas Akkaraju reported beneficial ownership of Eloxx Pharmaceuticals, Inc. common stock. Samsara BioCapital, L.P., Samsara BioCapital GP, LLC, Samsara Opportunity Fund, L.P., and Samsara Opportunity Fund GP, LLC each report beneficial ownership of 201,793 shares, representing 5.0% of Eloxx’s common stock.

Dr. Srinivas Akkaraju reports beneficial ownership of 403,586 shares, or 9.99% of the common stock, based on 4,036,314 shares outstanding as of June 10, 2026. The position includes, for each of Samsara LP and Samsara Opportunity Fund, 200,000 shares of common stock and Pre-Funded Warrants exercisable for up to 250,000 shares, subject to a 9.99% Beneficial Ownership Blocker that limits warrant exercise above that ownership level.

Nantahala Capital Management, LLC, together with Wilmot B. Harkey and Daniel Mack, reports beneficial ownership of common stock of Eloxx Pharmaceuticals, Inc..

As of June 30, 2026, the reporting persons may be deemed to beneficially own 400,000 shares of Eloxx common stock, representing 9.91% of the outstanding class. They report 0 shares with sole voting or dispositive power and 400,000 shares with shared voting and shared dispositive power. BLACKWELL PARTNERS LLC - SERIES A, a fund advised by Nantahala, has the right to receive or direct dividends and sale proceeds from more than five percent of these shares.

Eloxx Pharmaceuticals reported second quarter 2026 results and a business update, highlighting a significantly strengthened balance sheet following a public offering with gross proceeds of $66.0 million and an uplisting to the Nasdaq Capital Market. As of June 30, 2026, cash and cash equivalents were $62.0 million, including approximately $58.3 million in net proceeds from the June 2026 offering, and the company stated this cash is expected to fund operations into mid‑2028. Total stockholders’ equity improved to $46.4 million from a deficit of $(11.9) million at year‑end 2025.

For the three months ended June 30, 2026, net loss was $4.5 million, or $(0.66) per share, compared with $1.9 million, or $(5.45) per share a year earlier. Research and development expense rose to $2.8 million from $0.9 million, and general and administrative expense increased to $1.6 million from $0.7 million, mainly from higher clinical trial, personnel, and professional fees. For the first half of 2026, net loss was $8.3 million versus $3.6 million in 2025. In May 2026, the company completed a one‑for‑eleven reverse stock split and reduced authorized common shares from 500,000,000 to 100,000,000, and continues to advance its lead candidate exaluren in rare kidney disease indications.

Eloxx Pharmaceuticals, Inc. reported a net loss of $4.5 million for the quarter and $8.3 million for the six months ended June 30, 2026, up from $1.9 million and $3.6 million in the prior-year periods, driven by higher research and development and general and administrative expenses. Cash and cash equivalents rose to $62.0 million from $4.8 million at December 31, 2025, reflecting a $58.3 million June 2026 public offering and additional pre-funded warrant financings, which also eliminated remaining Hercules debt.

Total assets increased to $63.4 million and stockholders’ equity turned positive at $46.4 million, compared with a deficit of $11.9 million at year-end 2025. The company is advancing its lead candidate exaluren for rare kidney diseases, preparing a Phase 2b trial in nonsense mutation Alport syndrome in 2026 and a Phase 2 trial in nmADPKD in 2027, and remains eligible for up to $470.0 million in milestones plus royalties under its ZKN-013 license with Almirall. Management believes current liquidity will fund operations for at least 12 months, but a previously identified material weakness in internal control over financial reporting related to the financial close and reconciliation process remains under remediation.